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Across the United States, 34.1 million adults (13% of the adult 
population) have diabetes.1 However, 21.4% of US adults 
with diabetes are undiagnosed.1 Diabetes increases risk for 
numerous serious health issues, including: vascular disease, 
renal disease, blindness, neuropathy and amputation.1,2 
Patients with undiagnosed diabetes are at higher risk for 
stroke, coronary heart disease, and peripheral vascular 
disease.2 Additionally, 88 million adults (34.5% of the US 
adult population) have prediabetes, which is associated with 
an increased risk of progression to diabetes.1 Undiagnosed 
patients may be missing opportunities to make lifestyle 
changes or take medications that may decrease the risk of 
progression to diabetes.
Effective screening allows patients with prediabetes or 
diabetes to be diagnosed sooner, and timely treatment may 
result in decreased risk of associated complications.2 
Although multiple criteria exist, the United States Preventive 
Services Taskforce (USPSTF) limited criteria recommends 
screening adults aged 40 to 70 years who are overweight or 
obese ([body mass index] BMI ≥ 25kg/m2) every 3 years, 
and the expanded criteria recommend earlier screening for 
members of high risk racial/ethnic groups and people with 
a history of gestational diabetes or polycystic ovarian syn-
drome or a family history of diabetes.3
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Abstract
Introduction/Objectives: Diabetes and prediabetes impact nearly half of the US adult population and are associated 
with significant health risks but may be underdiagnosed. Effective screening may improve diagnosis and give patients 
opportunity to manage their disease. The purpose of this study was to determine screening rates, identify characteristics 
predictive of screening, and evaluate correct diagnosis of diabetes and prediabetes.
Methods: Retrospective chart review of 71 433 patients eligible for diabetes screening, defined by completing A1c test 
within the 3-year study period.
Results: A total of 31.3% of eligible patients received diabetes screening. Factors associated with screening include older 
age, female sex, non-white race, Hispanic ethnicity, Medicare or Medicaid insurance, higher BMI, and having a medical 
comorbidity. History of prediabetes or gestational diabetes were the strongest predictors for diabetes screening, but 
history of gestational diabetes was under-documented. Of those screened, 10.4% had a result consistent with diabetes and 
51.8% had a result consistent with prediabetes. However, 52.9% of these patients had a missed diagnosis.
Conclusions: Findings of this study indicate the need for uniform coverage for diabetes screening for all insurances, 
increased documentation of gestational diabetes to improve screening for patients with this history, and improving accurate 
diagnosis after screening is completed.
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One study showed that 76% of US adults met screening 
criteria; however, only 46.2% of those who met criteria 
were actually screened.4 Of those eligible for screening, 
3.7% had undiagnosed diabetes and 46.2% had undiag-
nosed prediabetes.4 Studies have consistently found higher 
rates of screening in patients with female sex, older age, 
higher body mass index, non-white race, comorbidities 
such as hypertension or dyslipidemia, and regular medical 
health care.4-6 One study on the impact of insurance showed 
that insured patients were more likely to receive screening.5 
Another study found that patients with private insurance 
were more likely to receive screening compared to patients 
with public insurance who were less likely to receive 
screening.6
The objectives of this study were to examine predictors 
of diabetes screening in a Practice and Community-Based 
Research Network (PCBRN). We further evaluated the 
number of patients who were screened for diabetes who 
received the correct diagnosis of prediabetes or diabetes.
Methods
To meet the study objectives, we conducted a retrospective 
chart review of patients of the PCBRN, which was 
composed of 50 urban, suburban, and rural primary care 
practices (33 Family Medicine, 14 Internal Medicine, and 
3 Family and Internal Medicine practices), including 4 
practices with resident physicians. Practices ranged in 
size from 1 to 58 clinicians with an average practice size 
of approximately 6 clinicians. There were 149 Family 
Medicine clinicians, including 14 residents, and 147 
Internal Medicine clinicians, including 37 residents. 
Patients of these practices were included if they had at least 
one visit with their Primary Care Practitioner (PCP) in the 
past 3 years and met USPSTF limited screening criteria 
(40-70 years of age and BMI ≥ 25 kg/m2).3 Screening based 
on this criteria has been found to have a sensitivity of 
47.3% and a specificity of 71.4%.7 This study excluded 
those with previously diagnosed diabetes or who were 
pregnant during the study period. Participants with a his-
tory of prediabetes were included if they met criteria for 
diabetes screening. We did not exclude patients with condi-
tions associated with increased erythrocyte turnover condi-
tions that would make A1c testing less accurate, such as 
malaria, blood loss, hemolysis, or chronic anemia.8
All data were extracted from the electronic medical 
record (EMR). The primary outcome was diabetes screen-
ing, measured by completion of a validated point-of-care or 
laboratory A1c test during the three-year study period 
(9/1/2016 to 8/31/2019). Fasting glucose was not used as 
the electronic health record did not specify if glucose test 
results were fasting or non-fasting. Predictor variables 
included demographics (age at study onset, sex, race, eth-
nicity, insurance type at study end), BMI at first visit during 
study period, PCP specialty (Family or Internal Medicine), 
and comorbidities at study end including: hypertension 
(I10), hyperlipidemia (E78.0–2, E78.4–5), prediabetes 
(including “impaired fasting glucose” or “impaired glucose 
tolerance”) (R73.01–03), polycystic ovarian syndrome 
(E28.2), and gestational diabetes (O24.4, Z86.32), and if 
obesity was listed on the patient’s problem list (E66–E66.9, 
Z68.3–45). These comorbidities were chosen due to their 
known risk association with type 2 diabetes.9,10 We also 
determined if patients’ A1c was consistent with prediabetes 
(A1c 5.7-7.4%) or diabetes (A1c ≥6.5%) and if patients 
had a diagnosis of prediabetes or diabetes added to their 
problem list during the three-year study period.
Data were analyzed to meet the study objectives using 
IMB SPSS, version 26. We first determined the percentage 
of eligible patients who completed diabetes screening. We 
then evaluated if any of the predictor variables were associ-
ated with the primary outcome of diabetes screening using 
logistic regression. We then determined what diagnoses 
were supported by A1c testing results and evaluated the 
number of patients who received the correct diagnosis. This 
study was approved by the Lehigh Valley Health Network 
Institutional Review Board.
Results
Most participants were white, non-Hispanic, and had com-
mercial insurance. Slightly over half of participants were 
female and over half had a Family Medicine PCP. While 
many patients had a diagnosis of hypertension (43%) or 
hyperlipidemia (41%), very few patients had a diagnosis of 
polycystic ovarian syndrome (0.2%) or a documented his-
tory of gestational diabetes (0.2%). Of the 71,433 patients 
who were eligible for screening, 22,379 (31.3%) completed 
diabetes screening with an A1c test (Table 1).
Demographic characteristic associated with higher odds 
of diabetes screening included older age, female sex, non-
white race, Hispanic ethnicity, seeing an Internal Medicine 
PCP, and having Medicaid or Medicare insurance. All 
comorbidities assessed were associated with higher odds of 
diabetes screening, with prediabetes (OR 8.78, 95% CI 
8.28-9.31) and a history of gestational diabetes (OR 6.01, 
95% CI 4.14-8.72) most strongly associated (Table 1). In 
addition, those who received screening had a significantly 
higher BMI than those who were not screened (mean differ-
ence 2.3 kg/m2, 95% CI 2.2-2.4).
Of the overall sample, 8299 (11.6%) received a diagnosis 
of prediabetes. However, 11 583 (51.8%) of those who had 
an A1c test had a result consistent with prediabetes. 55.9% 
of those patients meeting laboratory criteria for prediabetes 
did not receive a diabetes-related diagnosis. Of those who 
had an A1c result consistent with diabetes, 37.9% did not 
receive a diagnosis of diabetes, including 27.4% who did not 
receive any diabetes-related diagnosis (Table 2).
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Discussion and Conclusions
Overall 31.3% of participants completed diabetes screening 
within the 3 year study period. This rate is lower than rates 
seen in other studies which used fasting glucose as well as 
A1c and may be due to our restricted use of A1c only.4,5 
Consistent with prior studies, we did find an increased like-
lihood of screening in female patients, older patients, and 
patients with risk factors, including: non-white race, comor-
bidities, and higher BMI.4
Table 1. Demographics and Odds of Having A1c Screening for Diabetes for 71,433 Primary Care Patients Eligible for Diabetes 
Screening (40-70 years Old, Body Mass Index (BMI) ≥25 kg/m2, No Diagnosis of Diabetes On Start of Study, Not Pregnant During 
the Study).
Overall 
N = 71 433
A1c done 
N = 22 379 (31.3%)
A1c not done 





Age, years*† 55.8 (8.0) 57.0 (7.8) 55.3 (7.9) 1.03 (1.03-1.03) 1.01 (1.01-1.02)
Female sex‡§ 38 843 (54.4%) 11 624 (51.9%) 27 219 (55.5%) 0.87 (0.84-0.9) 0.85 (0.82-0.88)
Non-white race‡‖ 9053 (12.7%) 3145 (14.5%) 5908 (12.5%) 1.19 (1.13-1.24) 1.15 (1.09-1.23)
Hispanic ethnicity‡¶ 7327 (10.3%) 2709 (12.3%) 4618 (9.7%) 1.32 (1.25-1.39) 1.31 (1.22-1.4)
Internal Medicine PCP‡# 31 143 (43.6%) 9797 (43.8%) 21 346 (43.5%) 1.01 (0.98-1.04) 1.04 (1.0-1.08)
Insurance‡
 Commercial 46 662 (65.3%) 13 409 (60.3%) 33 253 (68.3%) Ref Ref
 Medicaid 6710 (9.4%) 2287 (10.3%) 4423 (9.1%) 1.28 (1.21-1.35) 1.25 (1.17-1.34)
 Medicare 15 214 (21.3%) 5848 (26.3%) 9366 (19.2%) 1.55 (1.49-1.61) 1.15 (1.09-1.21)
 Self-pay 2375 (3.3%) 711 (3.2%) 1664 (3.4%) 1.06 (0.97-1.16) 1.05 (0.94-1.16)
Comorbidities‡
 Hypertension 30 945 (43.3%) 12 394 (55.4%) 18 551 (37.8%) 2.04 (1.98-2.11) 1.38 (1.33-1.43)
 Hyperlipidemia 29 299 (41%) 11 982 (53.5%) 17 317 (35.3%) 2.11 (2.05-2.18) 1.61 (1.55-1.67)
 Prediabetes 8299 (11.6%) 6507 (29.1%) 1792 (3.7%) 10.8 (10.2-11.4) 8.78 (8.27-9.3)
 Polycystic ovarian syndrome 140 (0.2%) 78 (0.3%) 62 (0.1%) 2.76 (1.98-3.86) 2.81 (1.92-4.12)
 History gestational diabetes 152 (0.2%) 100 (0.4%) 52 (0.1%) 4.23 (3.02-5.92) 5.95 (4.09-8.64)
 BMI ≥30 kg/m2 39 451 (55.2%) 14 810 (66.8%) 24 641 (51.3%) 1.91 (1.85-1.97) 1.13 (1.08-1.19)
 Obesity on problem list 15 921 (22.3%) 7327 (32.7%) 8594 (17.5%) 2.29 (2.21-2.38) 1.43 (1.36-1.5)
 BMI (kg/m2)*† 32.1 (6.1) 33.7 (6.7) 31.4 (5.6) 1.06 (1.06-1.06) 1.04 (1.03-1.04)
*Variable reported as mean (SD).
†Change in odds of diagnosis with each unit increase in continuous variable.
‡Variable reported as n (%).
§Reference to male sex.
‖Reference to white race.
¶Reference to non-Hispanic ethnicity.
#Reference to Family Medicine PCP.
Table 2. Diagnoses Made for 71 433 Primary Care Patients Eligible for Diabetes Screening by A1c Screening Results.
No diabetes-related 
diagnosis made 







No A1c done (N = 49 054)† 47 189 1792 83
A1c does not support diabetes-related diagnosis (N = 8461)‡
 • All A1c <5.7%
7005 1439 21
A1c supports Prediabetes diagnosis (N = 11 583)§
 • A1c 5.7 to 6.4%
6479 4750 435
A1c supports diagnosis of diabetes (N = 2335)‖
 • A1c ≥6.5%
639 318 1451
*168 people total were diagnosed with both diabetes and prediabetes.
†10 people who did not have an A1c done were diagnosed with both diabetes and prediabetes.
‡4 people with A1c <5.7% were diagnosed with both diabetes and prediabetes.
§81 people with A1c 5.7 to 6.4% were diagnosed with both diabetes and prediabetes.
‖73 people with A1c ≥6.5% were diagnosed with both diabetes and prediabetes.
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In prior studies, health insurance, specifically private 
insurance coverage,5,6 was associated with diabetes screen-
ing, but this was not seen in our study as the rate of screen-
ing was not significantly different for patients without 
insurance. Interestingly, we did find an increased rate of 
screening for patients with Medicare or Medicaid. This may 
be due to variations in coverage between insurance types 
or a concern about copays. According to the Centers for 
Medicaid and Medicare, screening for diabetes is covered 
for those with hypertension, dyslipidemia, obesity, a history 
of high blood sugar, or 2 or more other risk factors, includ-
ing: age >65, overweight, family history of diabetes, or a 
history of gestational diabetes.9 Medicaid coverage for 
screening varies by state, but in most states screening for 
diabetes is covered with no or a very small copay.11 
Commercial insurance may have much wider variation in 
coverage and copay causing confusion for patients and cli-
nicians. In addition, patients with high deductible insurance 
may pay the full cost of tests that are not classified as 
“preventive.” We were only able to evaluate completed lab 
results and were not able to determine when labs were 
ordered but not completed by the patient.
We did note a significantly higher screening rate for 
patients with a history of gestational diabetes at 65.8%. This 
is consistent with other studies which found the rates for 
screening for women with a history of gestational diabetes 
was 67%.12 However, 6%-9% of pregnant women develop 
gestational diabetes,13 while only 0.2% of our sample had a 
documented history of gestational diabetes. This suggests 
the need to improve documentation of history of gestational 
diabetes to prevent clinicians missing this important risk 
factor and improve care for patients who need regular dia-
betes screening.
In this study 62.2% of the population screened had labs 
consistent with diabetes or prediabetes. This is consistent 
with the study by O’Brien, et al, which found a positive 
predictive value for the USPSTF limited criteria of 62% 
(95% CI 57.8-66.1).7 This suggests that the high rate of dia-
betes and prediabetes is not due to clinicians selecting high 
risk patients for screening, but rather is the true prevalence 
in the population and clinicians are potentially missing 
diagnoses for patients who were eligible but not screened. 
In addition, clinicians missed the diagnoses for 7363 
patients, 32.9% of those who were screened. Clinicians may 
benefit from EMR interventions including real-time remind-
ers to screen patients who meet eligibility criteria and inter-
pretation of results.
Strengths of this study were the large sample size and the 
inclusion of urban, suburban, and rural practices. The major 
limitations of this study were the retrospective chart review 
study design, which does not allow for the determination 
of causation in patient factors associated with screening, 
and use of EMR for data. The data extracted from the EMR 
limited the study to the use of completed A1c as we were 
unable to determine if glucoses were fasting or non-fasting 
or if labs had been ordered but not completed.
Opportunities for future research include evaluation of 
ordered but uncompleted labs to identify gaps in screening, 
as well as qualitative evaluation to understand the drivers 
for clinician recommendations and orders to screen for dia-
betes and patient completion of screening tests. This may 
lead to interventions to improve screening, such as EMR 
cues to prompt testing, assistance with accurate interpreta-
tion of A1c test results, and improved documentation of 
gestational diabetes history.
This study found a low rate of diabetes screening, but a 
high rate of diabetes and prediabetes in the population 
screened. Novel findings of this study include a higher 
rate of screening in populations receiving Medicare and 
Medicaid insurance. Patients may benefit from improved 
screening if both all insurance providers aligned their crite-
ria for screening with USPSTF and American Diabetes 
Association (ADA) recommendations. We also found a 
strong association between a history of gestational diabetes 
and diabetes screening but significant under-documentation 
of this history resulting in potential missed opportunities.
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